← Back to Search

Glucagon-like peptide-1 receptor agonist

Semaglutide for Obesity (LSS Trial)

Phase 3
Led By Warren Peters, MD
Research Sponsored by Loma Linda University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-75 years old
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up change between baseline and month four of treatment.
Awards & highlights

LSS Trial Summary

This trial is testing an anti-obesity medication to see how well it works in helping people lose weight and keep it off. The results could help lead to new medications for obesity.

Who is the study for?
This trial is for Hispanic/Latino individuals aged 18-75 with obesity (BMI >30). Participants must be able to consent and not have current cancer, eating disorders, history of bariatric surgery, genetic issues affecting study participation, allergies to semaglutide or related drugs, recent significant weight loss attempts, contraindications to semaglutide including certain thyroid cancers or syndromes, previous trial participation, diabetes types 1 or 2, pregnancy or plans to become pregnant soon.Check my eligibility
What is being tested?
The Latino Semaglutide Study is testing the effectiveness of a medication called Semaglutide at a dose of 2.4mg in helping lose and maintain weight loss compared against a placebo. The goal is to understand how this anti-obesity drug works which could lead to more treatments for obesity.See study design
What are the potential side effects?
Semaglutide may cause side effects such as digestive problems (nausea and diarrhea), potential allergic reactions if sensitive to the drug's components; long-term risks are not fully known but could include thyroid tumors based on its class warning.

LSS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am between 18 and 75 years old.

LSS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change between baseline and final study visit, seven months post baseline.
This trial's timeline: 3 weeks for screening, Varies for treatment, and change between baseline and final study visit, seven months post baseline. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of weight loss.
Secondary outcome measures
Food Addiction Assessment

LSS Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Intervention GroupActive Control1 Intervention
Will receive active medication semaglutide subcutaneously, once weekly, self-injection. Month 1 - 0.24 mg SC once weekly x 4 weeks.(IE-1) Month 2- 0.5 mg SC once weekly x 4 weeks.(IE-2) Month 3 -1 mg SC once weekly x 4 weeks.(IE-3) Month 4 - 1.7 mg SC once weekly x 4 weeks.(IE-4) Month 5 - 2.4 mg SC once weekly x 4 weeks. (IE-5) Month 6 - 2.4 mg SC continue once weekly x 8 weeks.(IE-6) Month 7 - completion visit (IE-7)
Group II: Control GroupPlacebo Group1 Intervention
Will receive placebo, subcutaneously, once weekly, self-injection throughout study duration.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for obesity often work through three primary mechanisms: appetite suppression, increased metabolism, and fat absorption inhibition. Appetite suppressants, such as GLP-1 agonists, reduce hunger and caloric intake by acting on the central nervous system. Medications that increase metabolism, like certain stimulants, enhance the body's energy expenditure, helping to burn more calories. Fat absorption inhibitors, such as orlistat, prevent the digestion and absorption of dietary fats, reducing overall caloric intake. These mechanisms are vital for obesity patients as they help manage weight by addressing both the intake and expenditure of calories, leading to more effective and sustainable weight loss.
Pharmacotherapy of obesity: emerging drugs and targets.

Find a Location

Who is running the clinical trial?

Loma Linda UniversityLead Sponsor
308 Previous Clinical Trials
261,020 Total Patients Enrolled
8 Trials studying Obesity
804 Patients Enrolled for Obesity
Novo Nordisk A/SIndustry Sponsor
1,525 Previous Clinical Trials
2,419,600 Total Patients Enrolled
144 Trials studying Obesity
132,350 Patients Enrolled for Obesity
Warren Peters, MD, MPHLead Sponsor

Media Library

Semaglutide (Glucagon-like peptide-1 receptor agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05087342 — Phase 3
Obesity Research Study Groups: Control Group, Intervention Group
Obesity Clinical Trial 2023: Semaglutide Highlights & Side Effects. Trial Name: NCT05087342 — Phase 3
Semaglutide (Glucagon-like peptide-1 receptor agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05087342 — Phase 3
Obesity Patient Testimony for trial: Trial Name: NCT05087342 — Phase 3
~5 spots leftby Aug 2024